- Home
- / ACELYRIN
ACELYRIN
ACELYRIN Summary
Company Summary
- Overview
- ACELYRIN is a clinical biopharmaceutical development company. It is engaged in the development and commercialization of therapeutic drug candidates for the treatment of uveitis, axial spondyloarthritis, hidradenitis suppurativa, psoriatic arthritis, and other immunological diseases.
- Type
- Subsidiary
- Status
- Active
- Founded
- 2020
- HQ
- Agoura Hills, CA, US | view all locations
- Website
- https://acelyrin.com
- Cybersecurity rating
Table of Contents
Key People
Alan Colowick, Director
Austin Ma, Senior Vice President, Investor Relations & Communications
Roberta Vespignani, Senior Medical Director, Head of Pharmacovigilance
LocationsView all
2 locations detected
Agoura Hills, CA HQ
United States
4149 Liberty Canyon Rd
South San Francisco, CA
United States
701 Gateway Blvd #300
ACELYRIN Financials
Summary Financials
- Net income (Q1, 2025)
- ($55.3M)
- Cash (Q1, 2025)
- $58.3M
- EBIT (Q1, 2025)
- ($59.9M)